These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 34812049)

  • 21. New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals.
    Chen J; Lu H
    Biosci Trends; 2021 May; 15(2):126-128. PubMed ID: 33746183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets.
    Farahani M; Niknam Z; Mohammadi Amirabad L; Amiri-Dashatan N; Koushki M; Nemati M; Danesh Pouya F; Rezaei-Tavirani M; Rasmi Y; Tayebi L
    Biomed Pharmacother; 2022 Jan; 145():112420. PubMed ID: 34801852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of Traditional Chinese Medicine and Systems Pharmacology in Drug Prevention and Treatment against COVID-19.
    Zhou W; Chen Z; Sun X; Zhong N; Liu Z
    Am J Chin Med; 2021; 49(5):1045-1061. PubMed ID: 34225580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
    Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies.
    Iacopetta D; Ceramella J; Catalano A; Saturnino C; Pellegrino M; Mariconda A; Longo P; Sinicropi MS; Aquaro S
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021.
    Yoo JH
    J Korean Med Sci; 2021 Feb; 36(6):e54. PubMed ID: 33559409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2: basic concepts, origin and treatment advances.
    Santos-López G; Cortés-Hernández P; Vallejo-Ruiz V; Reyes-Leyva J
    Gac Med Mex; 2021; 157(1):84-89. PubMed ID: 34125824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Looking beyond COVID-19 vaccine phase 3 trials.
    Kim JH; Marks F; Clemens JD
    Nat Med; 2021 Feb; 27(2):205-211. PubMed ID: 33469205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic modalities and novel approaches in regenerative medicine for COVID-19.
    Ramezankhani R; Solhi R; Memarnejadian A; Nami F; Hashemian SMR; Tricot T; Vosough M; Verfaillie C
    Int J Antimicrob Agents; 2020 Dec; 56(6):106208. PubMed ID: 33213829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the impact of vaccination strategies on the spread of COVID-19, including a novel household-targeted vaccination strategy.
    Voigt A; Omholt S; Almaas E
    PLoS One; 2022; 17(2):e0263155. PubMed ID: 35108311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.
    Bilal M; Iqbal HMN
    Hum Vaccin Immunother; 2020 Dec; 16(12):3034-3042. PubMed ID: 32845742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice.
    Paschall AV; Ozdilek A; Briner SL; Brindley MA; Avci FY
    Vaccine; 2022 Feb; 40(6):854-861. PubMed ID: 34991929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Precision therapeutic targets for COVID-19.
    Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
    Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection.
    Pei R; Feng J; Zhang Y; Sun H; Li L; Yang X; He J; Xiao S; Xiong J; Lin Y; Wen K; Zhou H; Chen J; Rong Z; Chen X
    Protein Cell; 2021 Sep; 12(9):717-733. PubMed ID: 33314005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five reasons why COVID herd immunity is probably impossible.
    Aschwanden C
    Nature; 2021 Mar; 591(7851):520-522. PubMed ID: 33737753
    [No Abstract]   [Full Text] [Related]  

  • 37. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.
    Fröba M; Große M; Setz C; Rauch P; Auth J; Spanaus L; Münch J; Ruetalo N; Schindler M; Morokutti-Kurz M; Graf P; Prieschl-Grassauer E; Grassauer A; Schubert U
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role and delicate balance of Host Immunity in Coronavirus Disease-19.
    Vyas AK; Varma V; Garg G; Gupta P; Trehanpati N
    Iran J Immunol; 2021 Mar; 18(1):1-12. PubMed ID: 33787510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 and antimalarials. Have we been doing it wrong all along?
    Cismaru CA; Cismaru GL; Seyed Nabavi F; Seyed Nabavi M; Berindan-Neagoe I
    Eur J Pharmacol; 2021 Jan; 891():173694. PubMed ID: 33130275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.